Please login to the form below
azacitidine
This page shows the latest azacitidine news and features for those working in and with pharma, biotech and healthcare.
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
Researchers found that Venclyxto (venetoclax) – known as Venclexta in the US – in combination with azacitidine extended overall survival (OS) compared to the azacitidine plus placebo arm. ... The safety profile of the treatment was found to be
Latest news
-
Givlaari, Rybelsus lead crowded CHMP recommendations
a host of other indications, as well as azacitidine betapharm (azacytidine) and azacitidine Mylan (azacitidine) for the treatment of a number of blood cancers.
-
BMS’ oral maintenance therapy boosts survival in AML patients
CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit
-
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial
Regulatory filings expected in first half of 2020. Celgene’s oral version of acute myeloid leukaemia (AML) chemotherapy azacitidine has hit the target in a phase 3 trial, setting up regulatory ... The formulation – known as CC-486 – is an
-
Tecentriq’s triple negative breast cancer use among key CHMP nods
The drug gained FDA approval in December 2017. Celgene also received a positive opinion for azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloidleukaemia.
-
Dutch biotech Argenx claims $1.8bn licensing deal with J&J
It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.
More from news
Approximately 2 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Sinopharm’s COVID-19 vaccine scores approval in China
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Gene Editing and Precision Medicine: The Future of Healthcare?
- CRM Design and Optimization for Life Science Organizations
- EMA begins rolling review process for Sputnik V COVID-19 vaccine
- MHRA to fast-track vaccines modified for new COVID-19 variants
- Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC
- Syneos Health Communications announces senior hires to Europe-based team
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
- A cultural shift in clinical research
- Research organisations across the board are experimenting with new technologies...
Quick links
Infographics
